Table 3.
Number of biomarker hits by compound and dose, of C15:0 (FA15) (D1 = 1.9, D2 = 5.6, D3 = 17, D4 = 50 µM), rapamycin (D1 = 0.3, D2 = 1, D3 = 3, D4 = 9 µM), metformin (D1 = 190, D2 = 560, D3 = 1700, D4 = 5000 µM), and acarbose (D1 = 1.1, D2 = 3.3, D3 = 10, D4 = 30 µM) among 12 primary human cell systems and 148 biomarkers mimicking various disease states. Biomarker hits include clinically relevant biomarker measurements in treated systems that were outside of the significance envelope (i.e., significantly different than non-treated control systems). Optimal dose was defined as the dose with the most biomarker hits.
| Compound | Number of Biomarker Hits by Increasing Dose | ||||
|---|---|---|---|---|---|
| D1 Lowest Dose |
D2 Lower Dose |
D3 Higher Dose |
D4 Highest Dose |
Optimal Dose (μM) | |
| C15:0 (FA15) | 28 | 56 | 81 | 40 | 17 |
| Rapamycin | 55 | 62 | 61 | 75 | 9 |
| Metformin | 9 | 5 | 28 | 53 | 5000 |
| Acarbose | 15 | 17 | 24 | 28 | 30 |